#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Lip and/or oral cavity cancer Acute leukaemia Aplastic anaemia Leukoencephalopathy Palmar-plantar erythrodysaesthesia syndrome Thymic carcinoma Univentricular heart Deafness neurosensory Myocarditis Adenoid cystic carcinoma Mitochondrial myopathy Chronic graft versus host disease in intestine Spina bifida Alpha-1 antitrypsin deficiency Dermatomyositis More trials…

    Learn about Rare Diseases

    Mucous membrane pemphigoid Immunodeficiency congenital – Diagnostics Splenic marginal zone lymphoma – Diagnostics Ornithine transcarbamoylase deficiency – Life with Disease Usher’s syndrome – Trials in Disease Soft tissue sarcoma – Treatment Crigler-Najjar syndrome – Treatment Encephalitis autoimmune – Treatment Myelodysplastic syndrome – Treatment Anaplastic thyroid cancer More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rigosertib Sodium Metoprolol Tartrate Immunoglobulins, Normal Human 4-Hydroxy-N-Desmethyltamoxifen Mosunetuzumab Ruxotemitide Larotrectinib Sulfate Azenosertib Gallium (68Ga) Chloride Haloperidol Festuca Elatior Pollen Extract Elenestinib Phosphate Hhalpc Ripretinib Zanubrutinib Metamizole Magnesium Cangrelor Tetrasodium Timrepigene Emparvovec Varnimcabtagene Autoleucel GSKVX000000017986 More therapies…

    Learn about Your Condition

    Mantle cell lymphoma Diabetic foot infection Postprandial hypoglycaemia Staphylococcal infection Labour induction Angiosarcoma non-metastatic Biliary tract operation Diverticulitis Transient ischaemic attack Ataxia telangiectasia Carcinoid tumour pulmonary Exfoliation glaucoma Lung transplant rejection Neurodegenerative disorder Leukoencephalopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2od Bgdarssvo Dg Sbvbma Mndvmkrrswk Bx 1rzr Myhqeccgwn 1cxizr Fliwgh

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Lorlatinib
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Nilotinib
    • Asciminib Hydrochloride
    Bulgaria Czechia France Germany Greece Hungary +4

  • Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Primary amyloidosis
    Investigated Drugs:
    • Anhydrous Cyclophosphamide
    • Bortezomib
    • Daratumumab
    Belgium Denmark France Germany Greece Hungary +5

  • Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Capivasertib
    • Abiraterone Acetate
    Belgium Bulgaria Czechia France Germany The Netherlands +3

  • Study on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Epstein-Barr virus associated lymphoma
    Investigated Drugs:
    • Ganciclovir Sodium
    • Nanatinostat
    • Valganciclovir
    France Germany Italy Spain

  • Study on Chemotherapy and Pelvic Reirradiation for Patients with Recurrent Rectal Cancer Using Irinotecan, Levoleucovorin, Fluorouracil, Oxaliplatin, and Capecitabine

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Fluorouracil
    • Irinotecan Hydrochloride Trihydrate
    France

  • Study of Pivekimab Sunirine for Adults with CD123-positive Acute Myeloid Leukemia and Other CD123-positive Blood Cancers

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Pivekimab Sunirine
    France Spain

  • Study on Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed, Refractory, or Newly Diagnosed Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Bortezomib
    • Carfilzomib
    • Daratumumab
    Denmark France Germany Greece Italy Spain

  • Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone to Bortezomib with Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Belantamab Mafodotin
    • Bortezomib
    • Dexamethasone
    Czechia France Germany Greece Italy Poland +1

  • Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    • Trastuzumab Emtansine
    Belgium Czechia Denmark France Germany Greece +7
Previous Page
1 … 34 35 36 37 38 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!